Athersys (NASDAQ:ATHX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX) in a research report report published on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Athersys has a 1-year low of $0.01 and a 1-year high of $1.99. The stock has a market cap of $833,000.00, a PE ratio of -0.01 and a beta of -0.90.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.